少数族裔系统性红斑狼疮患者免疫抑制剂用药障碍的定性研究
该定性描述性研究通过深度访谈12例服用口服免疫抑制剂的少数族裔SLE患者及12名狼疮门诊医生和工作人员,识别用药障碍。障碍分为能力(费用、药房、诊所)、机会(物流、药物)和动机(知识、信念、态度、身心健康)三类,最常见为费用、副作用、忙碌/遗忘和理解不足。建议干预应促进用药物流并提升动机,同时个体化。
要点
- 少数族裔SLE患者用药障碍涉及能力、机会和动机三个层面。
- 最常见障碍为费用、副作用、忙碌/遗忘和理解不足。
- 非依从患者多描述物流和内在障碍,依从患者多描述副作用。
核心结论
- 针对少数族裔SLE患者的用药障碍,干预应着重促进用药物流和提升动机,并允许个体化以应对差异。
研究设计与样本
- 定性描述性研究,对目的抽样的12例服用口服免疫抑制剂的少数族裔SLE患者及12名狼疮门诊医生和工作人员进行深度访谈。
主要发现
- 能力障碍包括获取药物的外部因素(费用、药房、诊所相关问题)。
- 机会障碍包括服药的物流和药物相关外部问题。
- 动机因素包括患者知识、信念、态度及身心健康等内在障碍。
- 最常见障碍为费用、副作用、忙碌/遗忘和理解不足。
- 非依从患者主要描述物流和内在障碍,依从患者主要描述副作用。
临床怎么用
- 临床应关注少数族裔SLE患者的用药障碍,针对物流和动机设计个体化干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Underrepresented racial and ethnic minorities are disproportionately affected by systemic lupus erythematosus (SLE). Racial and ethnic minorities also have more severe SLE manifestations that require use of immunosuppressive medications, and often have lower rates of medication adherence. We aimed to explore barriers of adherence to SLE immunosuppressive medications among minority SLE patients. METHODS: We conducted a qualitative descriptive study using in-depth interviews with a purposive sample of racial minority SLE patients taking oral immunosuppressants (methotrexate, azathioprine, or mycophenolate), and lupus clinic providers and staff. Interviews were audiorecorded, transcribed, and analyzed using applied thematic analysis. We grouped themes using the Capability, Opportunity, Motivation, Behavior conceptual model. RESULTS: We interviewed 12 SLE patients (4 adherent, 8 nonadherent) and 12 providers and staff. We identified capability barriers to include external factors related to acquiring medications, specifically cost-, pharmacy-, and clinic-related issues; opportunity barriers to include external barriers to taking medications, specifically logistic- and medication-related issues; and motivation factors to include intrinsic barriers, encompassing patients' knowledge, beliefs, attitudes, and physical and mental health. The most frequently described barriers were cost, side effects, busyness/forgetting, and lack of understanding, although barriers differed by patient and adherence level, with logistic and intrinsic barriers described predominantly by nonadherent patients and side effects described predominantly by adherent patients. CONCLUSION: Our findings suggest that interventions may be most impactful if they are designed to facilitate logistics of taking medications and increase patients' motivation while allowing for personalization to address the individual differences in adherence barriers.
引用
- Sun K, Corneli AL, Dombeck C, et al. Barriers to Taking Medications for Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers, and Clinic Staff. Arthritis Care Res (Hoboken). 2022. PMID: 33662174. doi:10.1002/acr.24591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。